Jefferies raised the firm’s price target on Replimune (REPL) to $19 from $16 and keeps a Buy rating on the shares. While still waiting for FDA’s acceptance of the company’s BLA, the firm feels “increasingly confident” that RP1 could be approved under accelerated approval path, which has been one of the key risks seen by investors, the analyst tells investors. The firm has increased its view of the odds of success of RP1 in aPD1 failed melanoma to 80% from 65%, leading to its price target increase.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REPL:
- Replimune 6.923M share Spot Secondary priced at $13.00
- Replimune announces proposed public offering of $125M of shares
- Amazon invests $4B more in Anthropic, Gap reports Q3 beat: Morning Buzz
- Replimune price target raised to $18 from $14 at BMO Capital
- Closing Bell Movers: Gap jumps 15% after Q3 earnings beat, guidance raise